PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy.
- DOI
- 10.1186/s13045-025-01768-1
- Published
- 2025-12-07
- Container
- J Hematol Oncol
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s13045-025-01768-1,
title = {PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy.},
author = {Wu YL and Wu L and Bi N and Cil T and Ge H and Zhu Z and Wang CL and Zhang W and Lv D and Mingyan E and Sun J and Pan Y and Krzakowski M and Dikilitas M and Sendur MAN and Kim YC and Yang Y and Mao R and Zhang B and Wang L.},
year = {2025},
journal = {J Hematol Oncol},
doi = {10.1186/s13045-025-01768-1},
url = {https://doi.org/10.1186/s13045-025-01768-1}
}RIS
TY - JOUR TI - PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy. AU - Wu YL AU - Wu L AU - Bi N AU - Cil T AU - Ge H AU - Zhu Z AU - Wang CL AU - Zhang W AU - Lv D AU - Mingyan E AU - Sun J AU - Pan Y AU - Krzakowski M AU - Dikilitas M AU - Sendur MAN AU - Kim YC AU - Yang Y AU - Mao R AU - Zhang B AU - Wang L. PY - 2025 JO - J Hematol Oncol DO - 10.1186/s13045-025-01768-1 UR - https://doi.org/10.1186/s13045-025-01768-1 ER -
APA
YL, W., L, W., N, B., T, C., H, G., Z, Z., CL, W., W, Z., D, L., E, M., J, S., Y, P., M, K., M, D., MAN, S., YC, K., Y, Y., R, M., B, Z., & L., W. (2025). PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy.. J Hematol Oncol. https://doi.org/10.1186/s13045-025-01768-1
Source records
- europe-pmc · retrieved 2026-09-27T12:26:36.638Z
- doaj · retrieved 2026-09-27T12:26:36.612Z